ANNALS OF PAKISTAN MEDICAL & ALLIED PROFESSIONALS

Efficacy of Ezetimibe Added to Statin Therapy in Patients with Familial Hypercholesterolemia

Authors

  • MUHAMMAD KASHIF ZAFAR

    Author

  • SHAHID IQBAL

    Author

  • SYED MAHMOOD-UL-HASSAN

    Author
DOI:
https://doi.org/10.53350/pakmedallied.01.01%20(April).01
Keywords:
Familial Hypercholesterolemia, Ezetimibe, Statin Therapy, Pakistan
Abstract
Objective: Cardiovascular diseases (CVD) are known to pose one of the major threats to life today, especially in developed countries. The main objective of the study is to find the efficacy of ezetimibe added to statin therapy in patients with familial hypercholesterolemia. Method: This randomized control trial (RCT) study was conducted at Punjab Institute of Cardiology Lahore from 1st July 2023 to 31st December 2023.  Data were collected from 185 patients. Blood samples were collected at baseline and at monthly intervals to measure lipid profiles. The efficacy analysis was conducted on an intention-to-treat basis, including all patients who received at least one dose of the study medication and had at least one post-baseline efficacy assessment. Results: We collected data from 185 patients. The baseline characteristics were well-matched between the groups, with an average age of 49.01 ± 10.28 years in the ezetimibe group and 50.01 ± 11.23 years in the placebo group, and both groups having 54% male participants. Baseline LDL-C levels were similar, with the ezetimibe group at 200 ± 30 mg/dL and the placebo group at 198 ± 32 mg/dL. 35% (32 patients) of the ezetimibe group achieved LDL-C levels below 70 mg/dL, compared to 12% (11 patients) in the placebo group (p<0.001). Additionally, 60% (55 patients) of the ezetimibe group reached LDL-C levels below 100 mg/dL, versus 25% (23 patients) in the placebo group (p<0.001). Conclusion: Adding ezetimibe to statin therapy significantly enhances LDL-C reduction and helps more patients with familial hypercholesterolemia achieve target cholesterol levels while maintaining a favorable safety profile.
References

1. Rosenson RS, Burgess LJ, Ebenbichler CF, Baum SJ, Stroes ES, Ali S, Khilla N, Hamlin R, Pordy R, Dong Y, Son V. Evinacumab in patients with refractory hypercholesterolemia. New England Journal of Medicine. 2020 Dec 10;383(24):2307-19.

2. Boutari C, Karagiannis A, Athyros VG. Rosuvastatin and ezetimibe for the treatment of dyslipidemia and hypercholesterolemia. Expert review of cardiovascular therapy. 2021 Jul 3;19(7):575-80.

3. Perez de Isla L, Liberopoulos E, Dovizio M, Veronesi C, Degli Esposti L, Zambon A. Differential Adherence to Free and Single-Pill Combination of Rosuvastatin/Ezetimibe: Findings from a Real-World Analysis in Italy. Advances in Therapy. 2024 Jul 4:1-2.

4. Ray KK, Ference BA, Séverin T, Blom D, Nicholls SJ, Shiba MH, Almahmeed W, Alonso R, Daccord M, Ezhov M, Olmo RF. World heart federation cholesterol roadmap 2022. Global heart. 2022;17(1).

5. Lewek J, Niedziela J, Desperak P, Dyrbuś K, Osadnik T, Jankowski P, Witkowski A, Bielecka‐Dąbrowa A, Dudek D, Gierlotka M, Gąsior M. Intensive statin therapy versus upfront combination therapy of statin and ezetimibe in patients with acute coronary syndrome: a propensity score matching analysis based on the PL‐ACS data. Journal of the American Heart Association. 2023 Sep 19;12(18):e030414.

6. Ray KK, Haq I, Bilitou A, Manu MC, Burden A, Aguiar C, Arca M, Connolly DL, Eriksson M, Ferrières J, Laufs U. Treatment gaps in the implementation of LDL cholesterol control among high-and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. The Lancet Regional Health–Europe. 2023 Jun 1;29.

7. Ray KK, Reeskamp LF, Laufs U, Banach M, Mach F, Tokgözoğlu LS, Connolly DL, Gerrits AJ, Stroes ES, Masana L, Kastelein JJ. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. European Heart Journal. 2022 Feb 21;43(8):830-3.

8. Visseren, F.L., Mach, F., Smulders, Y.M., Carballo, D., Koskinas, K.C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.M., Capodanno, D. and Cosyns, B., 2021. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). European heart journal, 42(34), pp.3227-3337.

9. Boytsov SA, Drapkina OM, Shlyakhto EV, Konradi AO, Balanova YA, Zhernakova YV, Metelskaya VA, Oshchepkova EV, Rotar OP, Shalnova SA. Epidemiology of cardiovascular diseases and their risk factors in regions of Russian Federation (ESSE-RF) study. Ten years later. Cardiovascular therapy and prevention. 2021 Aug 31;20(5):3007.

10. Bucholz EM, Rodday AM, Kolor K, Khoury MJ, de Ferranti SD. Prevalence and predictors of cholesterol screening, awareness, and statin treatment among US adults with familial hypercholesterolemia or other forms of severe dyslipidemia (1999–2014). Circulation. 2018 May 22;137(21):2218-30.

11. Barrios V, Pintó X, Escobar C, Varona JF, Gámez JM. Real-world attainment of low-density lipoprotein cholesterol goals in patients at high risk of cardiovascular disease treated with high-intensity statins: the TERESA study. Journal of clinical medicine. 2023 Apr 28;12(9):3187.

12. Katzmann JL, Sorio-Vilela F, Dornstauder E, Fraas U, Smieszek T, Zappacosta S, Laufs U. Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C. Clinical Research in Cardiology. 2022 Mar 1:1-0.

13. Hong SJ, Jeong HS, Ahn JC, Cha DH, Won KH, Kim W, Cho SK, Kim SY, Yoo BS, Sung KC, Rha SW. A phase III, multicenter, randomized, double-blind, active comparator clinical trial to compare the efficacy and safety of combination therapy with ezetimibe and rosuvastatin versus rosuvastatin monotherapy in patients with hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) randomized controlled trial. Clinical therapeutics. 2018 Feb 1;40(2):226-41.

14. Zhu Y, Hu H, Yang J, Yao Q, Xu H, Yu Y, Liu T, Lin S. The efficacy and safety of statin in combination with ezetimibe compared with double-dose statin in patients with high cardiovascular risk: a meta-analysis. Bosnian journal of basic medical sciences. 2020 May;20(2):169.

15. Lee J, Lee SH, Kim H, Lee SH, Cho JH, Lee H, Yim HW, Yoon KH, Kim HS, Kim JH. Low‐density lipoprotein cholesterol reduction and target achievement after switching from statin monotherapy to statin/ezetimibe combination therapy: Real‐world evidence. Journal of Clinical Pharmacy and Therapeutics. 2021 Feb;46(1):134-42.

16. Choi H, Kang SH, Jeong SW, Yoon CH, Youn TJ, Song WH, Jeon DW, Lim SW, Lee JH, Cho SW, Chae IH. Lipid-Lowering Efficacy of Combination Therapy With Moderate-Intensity Statin and Ezetimibe Versus High-Intensity Statin Monotherapy: A Randomized, Open-Label, Non-Inferiority Trial From Korea. Journal of Lipid and Atherosclerosis. 2023 Sep;12(3):277.

17. Lorenzi M, Ambegaonkar B, Baxter CA, Jansen J, Zoratti MJ, Davies G. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy. Clinical Research in Cardiology. 2019 May 1;108:487-509.

18. Ah YM, Jeong M, Choi HD. Comparative safety and efficacy of low-or moderate-intensity statin plus ezetimibe combination therapy and high-intensity statin monotherapy: A meta-analysis of randomized controlled studies. Plos one. 2022 Mar 4;17(3):e0264437.

19. Sakuma M, Toyoda S, Hashimoto R, Yazawa H, Masuyama T, Hirose S, Waku R, Hasumi H, Numao T, Abe S, Inoue T. Add-on ezetimibe treatment to low-dose statins vs medium-intensity statin monotherapy in coronary artery disease patients with poorly controlled dyslipidemia. Hypertension Research. 2019 Dec;42(12):1923-31.

20. Ah YM, Jeong M, Choi HD. Comparative safety and efficacy of low-or moderate-intensity statin plus ezetimibe combination therapy and high-intensity statin monotherapy: A meta-analysis of randomized controlled studies. Plos one. 2022 Mar 4;17(3):e0264437.

Cover Image
Published
2025-04-30
Issue
Vol. 1 No. 1 (April) (2025): Annals Pak Med
Section
Original Articles
License

Copyright (c) 2025 MUHAMMAD KASHIF ZAFAR, SHAHID IQBAL, SYED MAHMOOD-UL-HASSAN (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

Efficacy of Ezetimibe Added to Statin Therapy in Patients with Familial Hypercholesterolemia. (2025). ANNALS OF PAKISTAN MEDICAL & ALLIED PROFESSIONALS, 1(1 (April), 17-21. https://doi.org/10.53350/pakmedallied.01.01 (April).01

Most read articles by the same author(s)